CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $4.21M rose 10.3% year over year, behind the +13.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 11.8% from the prior quarter.

Context

  • Selling, general & admin amounted to 496.2% of revenue in FY2025, down 1792.6 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $133.78M (+670.7%) for the fiscal year ending Dec 2026, a step up from the +16.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.21M-11.8% QoQ
Last fiscal yearDec 2025
$17.36M+16.3% YoY
LTMMar 2026
$17.75M+13.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.3%+688.0%+677.7 pp
1 year+16.3%+670.7%+654.4 pp
3-year CAGR—+61.5%—
5-year CAGR+79.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
17.36M USD
Year-over-year change
+16.3%
4-year CAGR
-35.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +13.9% is the 3rd highest of 9, against a peer median of -9.1%.
  • Selling, general & admin amounts to 451.2% of revenue for CAMP, versus a peer median of 100.4%.
CAMP Competitors
Selling, General & Admin for CAMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$22.61M USD-10.5%+40.4%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$21.4M USD+37.8%+45.9%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$21.28M USD-23.4%-6.3%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$18.43M CAD+3.9%+1.8%100.4%
ATYRaTyr Pharma, Inc.LTM Mar 2026$17.76M USD+24.8%+12.7%9346.3%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$17.75M USD+13.9%—451.2%
VXRTVaxart, Inc.LTM Mar 2026$17.18M USD-7.7%-15.7%6.7%
BMEABiomea Fusion, Inc.LTM Mar 2026$16.17M USD-36.6%-2.6%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$15.9M USD-38.9%-12.9%—
Peer median (excluding CAMP) —-9.1%-0.4%100.4%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Nov 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.84M0350K652K3.5M
Cost of Revenue173.95M0001.64M
Gross Profit121.89M(947K)350K652K1.86M
Gross Margin41.2%—100.0%100.0%53.1%
Research & Development28.44M34.77M40.62M38.82M38.2M
Selling, General & Admin100.9M10.23M11.61M14.92M17.36M
Operating Expenses134.76M45M52.23M53.74M53.92M
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
EBITDA7.49M(44.12M)(50.2M)(51.39M)(50.42M)
EBITDA Margin2.5%—-14343.1%-7882.2%-1441.5%
Operating Income(15.31M)(45M)(51.88M)(53.09M)(52.06M)
Operating Margin-5.2%—-14822.6%-8142.3%-1488.3%
Interest Income002.81M1.33M2.17M
Interest Expense15.32M6.26M000
Other Income / Expenses(14.75M)809K2.59M1.3M(28.34M)
Income Before Tax(30.06M)(44.19M)(49.29M)(51.79M)(80.4M)
Pre-Tax Margin-10.2%—-14083.1%-7943.4%-2298.5%
Income Tax Expense1.09M0000
Net Income(31.15M)(44.19M)(49.29M)(51.79M)(80.4M)
Net Margin-10.5%—-14083.1%-7943.4%-2298.5%
EPS (Basic)(0.88)(0.90)(4.07)(2.66)(2.65)
EPS (Diluted)(0.88)(0.90)(4.07)(2.66)(2.65)
Weighted Avg Shares35.25M36.1M12.12M19.51M30.38M
Weighted Avg Shares (Diluted)35.25M36.13M12.12M19.51M30.38M

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.